MA38250B1 - Nouveau dérivés d'hydantoïne pour leurs utilisations dans le traitement de maladies, comme l'osteoporose et la thrombocytopenie - Google Patents

Nouveau dérivés d'hydantoïne pour leurs utilisations dans le traitement de maladies, comme l'osteoporose et la thrombocytopenie

Info

Publication number
MA38250B1
MA38250B1 MA38250A MA38250A MA38250B1 MA 38250 B1 MA38250 B1 MA 38250B1 MA 38250 A MA38250 A MA 38250A MA 38250 A MA38250 A MA 38250A MA 38250 B1 MA38250 B1 MA 38250B1
Authority
MA
Morocco
Prior art keywords
thrombocytopenia
osteoporosis
diseases
treatment
hydantoin derivatives
Prior art date
Application number
MA38250A
Other languages
English (en)
Other versions
MA38250A1 (fr
Inventor
Yoshikazu Nishimura
Toru Esaki
Tatsuya Tamura
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MA38250A1 publication Critical patent/MA38250A1/fr
Publication of MA38250B1 publication Critical patent/MA38250B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne un composé qui peut être représenté par la formule générale (1) ou un sel pharmacologiquement permis de celui-ci. (1) (dans la formule, r1, r2, r3 et r4 sont tels que définis dans les revendications.)
MA38250A 2012-12-10 2013-12-10 Nouveau dérivés d'hydantoïne pour leurs utilisations dans le traitement de maladies, comme l'osteoporose et la thrombocytopenie MA38250B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012269178 2012-12-10
PCT/JP2013/083022 WO2014092061A1 (fr) 2012-12-10 2013-12-10 Dérivé d'hydantoïne

Publications (2)

Publication Number Publication Date
MA38250A1 MA38250A1 (fr) 2017-02-28
MA38250B1 true MA38250B1 (fr) 2017-10-31

Family

ID=50934349

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38250A MA38250B1 (fr) 2012-12-10 2013-12-10 Nouveau dérivés d'hydantoïne pour leurs utilisations dans le traitement de maladies, comme l'osteoporose et la thrombocytopenie

Country Status (35)

Country Link
US (5) US9428505B2 (fr)
EP (1) EP2930176B1 (fr)
JP (1) JP5951799B2 (fr)
KR (1) KR102168738B1 (fr)
CN (1) CN104854106B (fr)
AU (1) AU2013358167B2 (fr)
BR (1) BR112015012411B1 (fr)
CA (1) CA2892621C (fr)
CL (2) CL2015001391A1 (fr)
CR (1) CR20150272A (fr)
DK (1) DK2930176T3 (fr)
ES (1) ES2663797T3 (fr)
HK (1) HK1209735A1 (fr)
HR (1) HRP20180647T1 (fr)
HU (1) HUE037530T2 (fr)
IL (1) IL238277B (fr)
LT (1) LT2930176T (fr)
MA (1) MA38250B1 (fr)
MX (1) MX2015007309A (fr)
MY (1) MY178583A (fr)
NO (1) NO2930176T3 (fr)
NZ (1) NZ707946A (fr)
PE (1) PE20151295A1 (fr)
PH (1) PH12015501146B1 (fr)
PL (1) PL2930176T3 (fr)
PT (1) PT2930176T (fr)
RS (1) RS57190B1 (fr)
RU (1) RU2678984C2 (fr)
SA (1) SA515360528B1 (fr)
SG (1) SG11201504204XA (fr)
SI (1) SI2930176T1 (fr)
TW (1) TWI615394B (fr)
UA (1) UA115072C2 (fr)
WO (1) WO2014092061A1 (fr)
ZA (1) ZA201503597B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010126030A1 (fr) 2009-04-28 2010-11-04 中外製薬株式会社 Dérivé de spiroimidazolone
JP5951799B2 (ja) * 2012-12-10 2016-07-13 中外製薬株式会社 ヒダントイン誘導体
CN106572994B (zh) * 2014-06-09 2020-09-18 中外制药株式会社 含有乙内酰脲衍生物的药物组合物
WO2020027011A1 (fr) 2018-07-30 2020-02-06 中外製薬株式会社 Dispersion solide de dérivé d'hydantoïne
CN110464002A (zh) * 2019-09-12 2019-11-19 西南石油大学 一种天然冰粉的制备方法及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1135470A (ja) * 1997-07-23 1999-02-09 Teijin Ltd ビタミンｄ３誘導体を含有する副甲状腺ホルモン産生促進剤
EP1137640B1 (fr) 1998-12-11 2005-09-21 F. Hoffmann-La Roche Ag Derives cycliques de l'hydrazine comme inhibiteurs tnf-alpha
US7004593B2 (en) * 2002-06-06 2006-02-28 Donnelly Corporation Interior rearview mirror system with compass
US20050101574A1 (en) * 2000-08-30 2005-05-12 Seiichi Ishizuka Parathyroid hormone production inhibitors containing vitamin d3 derivatives
KR20040004412A (ko) * 2000-10-26 2004-01-13 화이자 프로덕츠 인크. 스피로-피리미딘-2,4,6-트리온 메탈로프로테이나제 억제제
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
AR038658A1 (es) * 2001-06-15 2005-01-26 Novartis Ag Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento
US20070099940A1 (en) * 2004-02-11 2007-05-03 Spearing Paul K Pth agonists
JP2007522215A (ja) * 2004-02-11 2007-08-09 スミスクライン・ビーチャム・コーポレイション Ｐｔｈアゴニスト
AU2005294448B2 (en) 2004-10-07 2011-07-14 Merck Sharp & Dohme Corp. CGRP receptor antagonists
WO2007135417A1 (fr) 2006-05-19 2007-11-29 James Black Foundation Dérivés de benzotriazépinone
MX2008016273A (es) 2006-06-20 2009-01-15 Wyeth Corp Inhibidores de canal de potasio kv1.5.
ES2351378T3 (es) 2007-06-07 2011-02-03 F. Hoffmann-La Roche Ag Derivados de prolinamida como antagonistas de nk3.
CL2008003651A1 (es) 2007-12-10 2009-06-19 Novartis Ag Compuestos derivados de 3,5-diamino-6-cloropirazinamida sustituida; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una condición inflamatoria o alergica, en particular una enfermedad inflamatoria u obstructiva de las vias respiratorias.
US7981904B2 (en) 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
US8513193B2 (en) 2008-10-13 2013-08-20 University Of Rochester Protecting and repairing cartilage and musculoskeletal soft tissues
WO2010126030A1 (fr) 2009-04-28 2010-11-04 中外製薬株式会社 Dérivé de spiroimidazolone
JP5951799B2 (ja) * 2012-12-10 2016-07-13 中外製薬株式会社 ヒダントイン誘導体
CN106572994B (zh) * 2014-06-09 2020-09-18 中外制药株式会社 含有乙内酰脲衍生物的药物组合物

Also Published As

Publication number Publication date
SI2930176T1 (en) 2018-06-29
HRP20180647T1 (hr) 2018-06-01
TWI615394B (zh) 2018-02-21
IL238277A0 (en) 2015-06-30
HK1209735A1 (en) 2016-04-08
IL238277B (en) 2018-01-31
US20160326175A1 (en) 2016-11-10
AU2013358167B2 (en) 2017-09-14
PT2930176T (pt) 2018-04-03
US20220162208A1 (en) 2022-05-26
MX2015007309A (es) 2015-09-10
NZ707946A (en) 2019-11-29
RS57190B1 (sr) 2018-07-31
CN104854106A (zh) 2015-08-19
ES2663797T3 (es) 2018-04-17
PH12015501146A1 (en) 2015-08-10
RU2678984C2 (ru) 2019-02-05
EP2930176B1 (fr) 2018-02-07
CR20150272A (es) 2015-07-09
EP2930176A4 (fr) 2016-06-01
LT2930176T (lt) 2018-04-10
US20150274727A1 (en) 2015-10-01
MA38250A1 (fr) 2017-02-28
US9428505B2 (en) 2016-08-30
SA515360528B1 (ar) 2018-05-24
EP2930176A1 (fr) 2015-10-14
US20180237436A1 (en) 2018-08-23
RU2015127624A (ru) 2017-01-16
CN104854106B (zh) 2017-07-04
CA2892621C (fr) 2021-02-16
KR20150092275A (ko) 2015-08-12
MY178583A (en) 2020-10-16
NO2930176T3 (fr) 2018-07-07
BR112015012411B1 (pt) 2021-10-05
WO2014092061A1 (fr) 2014-06-19
CL2015001391A1 (es) 2015-07-31
HUE037530T2 (hu) 2018-09-28
TW201439092A (zh) 2014-10-16
JPWO2014092061A1 (ja) 2017-01-12
CA2892621A1 (fr) 2014-06-19
PL2930176T3 (pl) 2018-07-31
ZA201503597B (en) 2016-09-28
AU2013358167A1 (en) 2015-04-09
UA115072C2 (uk) 2017-09-11
CL2017000069A1 (es) 2017-08-25
BR112015012411A2 (pt) 2017-07-11
SG11201504204XA (en) 2015-07-30
US20210024524A1 (en) 2021-01-28
KR102168738B1 (ko) 2020-10-22
PH12015501146B1 (en) 2015-08-10
PE20151295A1 (es) 2015-10-10
DK2930176T3 (en) 2018-03-19
JP5951799B2 (ja) 2016-07-13

Similar Documents

Publication Publication Date Title
MA42109A (fr) Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase
TN2015000347A1 (fr) Azabenzimidazoles servant d'inhibiteurs d'isoenzymes pde4 pour le traitement de troubles du snc et d'autres troubles
MA33636B1 (fr) Dérivés aminopropioniques substitués comme inhibiteurs de néprilysine
MA42410A (fr) Oxystérols et leurs méthodes d'utilisation
MA37762B1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA40225B1 (fr) Composés dihydroisoquinolinone substitués
MA38403A1 (fr) Nouveaux dérivés de pyrazole modulateurs specifiques de cb2
MA40955A (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA34797B1 (fr) Hétéroaryles et leurs utilisations
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
MA35275B1 (fr) Composés de tétrahydropyridopyridine et tétrahydropyridopyrimidine et utilisation de ceux-ci en tant que modulateurs de récepteur c5a
MA39152A1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
MA38250A1 (fr) Nouveau dérivés d'hydantoïne pour leurs utilisations dans le traitement de maladies, comme l'osteoporose et la thrombocytopenie
MA41238B1 (fr) Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit
MA38330B1 (fr) Dérivés d'acide phosphonique butanoïque de bisphénol substitués en qualité d'inhibiteurs de nep (endopeptidase neutre)
MA37765A1 (fr) Composés de pyrazole substitués utilisés comme antagonistes de lpar
MA39170A1 (fr) Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer
MA38410A1 (fr) Composés d'azétidinyloxyphénylpyrrolidine
MA39983B1 (fr) Dérivés de carboxamide
MA38679A1 (fr) Modulateurs du récepteur de cxcr7
MA34098B1 (fr) Utilisation de nouveaux inhibiteurs pan-cdk pour le traitement de tumeurs
MA39253A1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr
MA38559B1 (fr) Dérivés d'imidazo-triazine utilisés comme inhibiteurs de la pde10
MA37849A1 (fr) Dérivés de diazépinone à utiliser pour le traitement du syndrome de l'x fragile, de la maladie de parkinson ou de la maladie du reflux